Tibsovo (ivosidenib) is a groundbreaking prescription medication specifically designed for adults with an isocitrate dehydrogenase-1 (IDH1) mutation. This targeted therapy represents a significant advancement in the treatment of certain types of cancer, providing new hope for patients with limited options.
Tibsovo is a prescription medication prescribed for adults who have an isocitrate dehydrogenase-1 (IDH1) mutation. It is used in the following conditions:
- Newly diagnosed AML, either in combination with azacitidine or alone, for individuals aged 75 years or older, or those unable to tolerate certain chemotherapy treatments due to health issues.
- AML that has relapsed or has not responded to prior treatment(s).
- MDS that has relapsed or has not responded to previous treatment(s).
- For bile duct cancer that has metastasized and has already been treated with previous therapy.
Your healthcare provider will conduct tests to determine if Tibsovo is suitable for you. The safety and effectiveness of Tibsovo in children have not been established.
Mechanism of Action:
Ivosidenib, a small molecule inhibitor, targets mutant IDH1 enzymes in AML patients with specific mutations. Effective outcomes are linked to reduced 2-HG levels and remissions. In vitro and in vivo studies confirm lowered 2-HG levels and increased myeloid cells. The Cholangiocarcinoma model also sees reduced 2-HG levels.
Side Effects:
Tibsovo may result in side effects, just like other medicines. Nausea, diarrhoea, exhaustion, and joint discomfort are examples of frequent side effects. Additionally, patients may develop differentiation syndrome, a potentially serious condition that needs prompt medical treatment. Any new or deteriorating symptoms must be immediately discussed with your healthcare professional.
- Differentiation Syndrome in AML
Patients treated with Tibsovo with relapsed or refractory AML experienced differentiation syndrome. One should initiate dexamethasone, if differentiation syndrome is suspected, 10 mg IV every 12 hours and hemodynamic monitoring until improvement. If severe symptoms persist for more than 48 hours after initiation of corticosteroids, stop Tibsovo administration until symptoms are no longer severe.
- QTc Interval Prolongation
There are cases of patients treated with Tibsovo who can develop QTc prolongation and ventricular arrhythmias. One should interrupt Tibsovo if QTc exceeds more than 480 msec and less than 500 msec. And interrupt and decrease the drug if QTc increases to greater than 500 msec. One should permanently discontinue Tibosovo in patients who develop QTc interval prolongation with signs of life threatening arrhythmia.
Tibsovo must be stored and handled correctly to maintain its efficacy and safety. Keep the medication stored at a temperature range of 20°C-25°C, with excursions allowed between 15°C to 30°C.
What documents are required to import Trodelvy?
Tibsovo (Ivosidenib) tablets can be imported by patients or government hospitals on behalf of patients. The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of the respective country).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is Tibsovo available worldwide?
Tibsovo (Ivosidenib) tablet is a prescription pharmaceutical drug that legally requires a medical prescription for dispensation.
Indian Pharma Network (IPN) facilitates the import of critical medications like Tibsovo globally, ensuring the named patient supply (NPS). IPN is the facilitator that provides essential support for:
- Availability of Tibsovo (Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka).
- Tibsovo available in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc
- Determining Medicine Price.
- Sourcing genuine and reliable sources from the USA, Canada, Europe, and Australia.
- Ensuring 100% transparency.
Tibsovo can be made available to patients, doctors, and hospitals in various countries across the globe. The order will be confirmed only after receiving a valid prescription from the doctor and, if required, an import permit.
Indian Pharma Network (IPN) can facilitate the supply of Tibsovo (prescription medicine) to locations worldwide while adhering to legal requirements (if applicable).
For inquiries about the price of Trodelvy, please contact:
Phone: +91-9310090915 | Toll-Free Number: 1800-889-1064
Email: info@indianpharmanetwork.in
We assure quality and worldwide delivery as per the buyer’s specifications.
Indian Pharma Network is proficient in sourcing Tibsovo (Ivosidenib) from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide in countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.
Indian Pharma Network (IPN) is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address. Your health and well-being are our top priorities
What is the Generic Name for the trade name drug Tibsovo®?
Ivosidenib is Generic Name for the trade name drug Tibsovo®.
What is the Manufacturer Name of Tibsovo®?
Tibsovo® is manufactured by Servier Pharmaceuticals.
Is Tibsovo® approved by the FDA?
Yes, Tibsovo® is approved by the FDA. Date of first/initial approval: July 20, 2018.
Where can I get Tibsovo® at the best price in India?
To get the best tibsovo 250 mg tablet price in India, contact Indian Pharma Network (WHO-GDP & ISO 9001:2008 authorized Company). A medical prescription is required while buying Tibsovo®.
What is the dosage and form of Tibsovo® supplied?
Tibsovo® is supplied as Tablets: 250 mg for oral administration.
What are the most common side effects with Tibsovo® when used along with azacitidine or alone in adults with AML?
The most common side effects with Tibsovo® when used in along with azacitidine or alone in adults with AML include: changes in certain blood cell counts, diarrhea, increased blood sugar, fatigue, changes in certain liver function tests, swelling of arms or legs, decreased levels of electrolytes in the blood, nausea, vomiting, decreased appetite, joint pain, shortness of breath, uric acid increased, stomach (abdominal) pain, changes in certain kidney function tests, pain or sores in your mouth or throat, rash, irregular heart rhythm or heartbeat (QTc prolongation), differentiation syndrome, and muscle pain.
What are the most common side effects with Tibsovo® when used in patients with cholangiocarcinoma?
The most common side effects (≥15%) in patients with cholangiocarcinoma are fatigue, nausea, abdominal pain, diarrhea, cough, decreased appetite, ascites, vomiting, anemia, and rash.
How much does Tibsovo® cost in India?
Tibsovo cost in India is less and can vary. To buy/procure this IDH1 inhibitor authentically, you can Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Tibsovo®?
Tibsovo® is available as 250 mg tablets. Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).
Is it safe to buy Tibsovo® online from India?
Yes, You can buy tibsovo tablets in India online at the best price from Indian Pharma Network if Tibsovo® has not been approved or is not available in your country.
What is the latest FDA approval for Tibsovo?
The FDA has recently approved Tibsovo for the treatment of relapsed or refractory myelodysplastic syndromes (MDS) with an IDH1 mutation. This approval is based on the results of a Phase I clinical trial, which demonstrated significant efficacy in this patient population.
How does Tibsovo work in treating MDS?
Tibsovo targets and inhibits the mutant IDH1 enzyme, which is involved in the abnormal proliferation of cancer cells. By inhibiting this enzyme, Tibsovo helps to reduce the growth and spread of cancer cells in patients with IDH1-mutated MDS.
Is Tibsovo available in South Asia?
Tibsovo tablets are available in Asian countries like Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka.
What are the key findings from the clinical trials of Tibsovo for MDS?
The clinical trial showed a complete remission rate of 38.9% and an objective response rate of 83.3%. The median time to complete remission was 1.9 months. These results indicate that Tibsovo is highly effective in inducing remission in patients with IDH1-mutated MDS.
Is there any specific diagnostic test required before starting Tibsovo?
Yes, the Abbott RealTime IDH1 Assay diagnostic device has been approved to help identify patients with IDH1 mutations who may benefit from Tibsovo. This test ensures that the treatment is targeted to patients most likely to respond.
Is Tibsovo available in Maldives?
Yes, Indian Pharma Network (IPN) can facilitate the supply of Tibsovo to Maldives while adhering to legal requirements.
Tibsovo a chemotherapy drug?
Acute myeloid leukemia (AML), a form of cancer, is treated with tibsovo. It is not, however, a chemotherapy medicine.
Where is Tibsovo available in India?
Tibsovo available in India (Noida, Delhi, Mumbai, Gurgaon, Lucknow, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc
